Anti-Dumping Alert: Nitisinone Capsules (Sweden)

Nitisinone Capsules: Dumping (Sweden)

On September 21, 2018, the CBSA initiated an investigation respecting the alleged injurious dumping of nitisinone capsules from Sweden.  The investigation follows a complaint filed by Laboratoirs KABS Inc. and MendeliKABS Inc.

The goods in question are normally classified under the following tariff classification numbers:

3003.90.00.90

3004.90.00.79

3004.90.00.90

The subject goods are defined in the Complaint as:

Capsules and tablets of nitisinone with a dosage of 2 mg, 5 mg, 10 mg and 20 mg, whether or not they are packaged for retail, originating in or exported from the Kingdom of Sweden.

 Additional product information can be found here.

The list of potential exporters and Statement of Reasons are here.

For the full list of documents filed with the CBSA so far, click here.

The Investigation Schedule:

September 21, 2018 Initiation of the CBSA’s dumping investigation
October 5, 2018 Statement of Reasons issued regarding the initiation of the investigations
October 15, 2018 Importer responses to CBSA’s Request for Information due
October 30, 2018 Exporter responses to CBSA’s Request for Information due
December 20, 2018 Preliminary Determinations or termination of the CBSA’s dumping investigation
January 4, 2019 Statement of Reasons issued (Preliminary Determinations or termination)

In the event of preliminary determinations of dumping:

December 20, 2018 Exporter and Importer ruling letters available
January 28, 2019, at noon Closing of the Record date
February 4, 2019, by noon Case Arguments due from all parties
February 11, 2019, by noon Reply Submissions due from all parties in respect of Case Arguments
March 20, 2019 Final Determinations or termination of the CBSA’s dumping and subsidy investigations
March 20, 2019 Exporter and Importer ruling letters available
April 4, 2019 Statement of Reasons issued (Final Determinations or termination)

 

The CITT:

The CITT has initiated at preliminary injury inquiry in order to determine whether the evidence discloses a reasonable indication that the dumping of capsules and tablets of nitisinone with a dosage of 2 mg, 5 mg, 10 mg and 20 mg, whether or not they are packaged for retail, originating in or exported from the Kingdom of Sweden, has caused injury or retardation or is threatening to cause injury, as these words are defined in SIMA.

 

Stay Tuned…

We will be providing updates on this blog on the CBSA investigation and the CITT’s injury inquiry as they become available.

 

John Reiterowski, DS Lawyers Canada, LLP

jreiterowski@dsavocats.ca

DS Customs & Trade team located in Paris, Brussels, Montreal, Toronto, Lima, Singapore, Vietnam, Beijing, Guangzhou, Dakar and Cotonou is at your disposal to provide you with additional information.

CONTACT US:

dscustomsdouane@dsavocats.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s